• New Test Looks at Unique Response of MS Patients to Epstein-Barr Virus

    Bio-IT World | Significant evidence now exists implicating the Epstein-Barr virus (EBV) as a causal factor in the development of multiple sclerosis (MS), making treatment of the virus a priority. To that end, research scientists at Trinity College Dublin have developed a blood test to measure the immune response to EBV that could be used as an outcome measure in future clinical trials in people with established MS.

    May 15, 2024

  • AI System For Diagnosing Rare Diseases and Solving Medical Cold Cases

    Bio-IT World | Using an artificial intelligence (AI) model that was trained on millions of variants from identified genetic disorders and incorporates the complex decision-making process of human molecular scientists, investigators at Baylor College of Medicine are on track to automate the diagnosis of an enormous number of undiagnosed conditions.

    May 14, 2024

  • The Replication Crisis: How Can Open Science Improve the Scale of Reproducibility?

    Bio-IT World | For years, two of the key principles of science have been replication and the ability to produce consistent results. Yet, scientists across fields today are still grappling with challenges in ensuring the repeatability and reliability of their findings. More recently, this has been referred to as the ‘replication crisis’ or ‘reproducibility crisis’ and details the growing concerns around the lack of reproducibility in scientific studies.

    May 10, 2024

  • Digital Twin of Infant Microbiome Reliably Predicts Cognitive Deficits

    Bio-IT World | Researchers at the University of Chicago have succeeded in creating a digital twin of the gut microbiome of premature infants that reliably models the many interactions taking place between quickly changing bacterial inhabitants. The so-called “Q-net” model, created with generative artificial intelligence (AI), was used to make predictions about which infants were going to have neurodevelopmental deficits using head circumference as the proxy.

    May 8, 2024

  • Hype and Disruption: Post-Dagdigian Trends Talk Splits in Two

    Bio-IT World | It finally happened. After being absent from last year’s “Trends from the Trenches” talk at the Bio-IT World Conference & Expo, BioTeam cofounder Chris Dagdigian has officially retired from delivering the traditional conference-closer.

    May 7, 2024

  • Digital Twins in an Expansive Future

    Bio-IT World | The practice of medicine has struggled to adopt data-driven tools, Dr. Caroline Chung told the audience at last month’s Bio-IT World Conference & Expo. Even when tools are developed, getting them into clinical practice has been slow.

    May 2, 2024

  • Novel Diagnostic System Finds Role of Immune System in Alzheimer’s Disease

    Bio-IT World | Researchers in Denmark have devised a blood-based diagnostic technique that can detect even trace amounts of an aggregated protein indicative of Alzheimer’s disease before any disease-related changes show up on a PET scan, one of the traditional testing methods.

    May 1, 2024

  • Arena Bioworks: Changing the Incentive Model for Biomedical Research

    Bio-IT World | Last week, Steve Pagliuca was flying to Milan to catch an Atalanta football match, an Italian professional football club of which he is part owner. But before his flight, he stopped to talk biotech at the Bio-IT World Venture, Innovation & Partnering Conference held in conjunction with the Bio-IT World Conference & Expo.

    Apr 30, 2024

  • Ginkgo Bioworks, Novo Nordisk Partnership, Mission Bio Updates Platform, PathAI, Google Cloud Team Up, More

    Bio-IT World | Ginkgo Bioworks has expanded its strategic partnership with Novo Nordisk; Mission Bio introduced sample multiplexing features for the company’s Tapestri Platform; PathAI announced a strategic partnership with Google Cloud at Bio-IT World Conference & Expo to help biopharma companies and anatomic pathology labs accelerate the adoption of AI and digital pathology; more.

    Apr 25, 2024

  • Follow the Money: Lymphatic System Platform, Endovascular Device System, Generative AI For Small Molecule Therapies, More

    Bio-IT World | Seaport Therapeutics plans to advance their Glyph platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms and has demonstrated clinical proof-of-concept; Nectero Medical will accelerate the execution of the Phase II/III (stAAAble) trial and to support the submission of a New Drug Application with the U.S. Food and Drug Administration for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST) System; DeepCure will further develop its generative AI and physics-based engine to innovate the discovery of small molecule therapies for challenging targets; more.

    Apr 24, 2024

  • AI Ushers in HPC Revival Says TACC’s Dan Stanzione

    Bio-IT World | High performance computing is enjoying an extreme vindication, said Dan Stanzione, Associate Vice President for Research at The University of Texas at Austin and Executive Director of TACC. In the opening plenary presentation at last week’s Bio-IT World Conference & Expo, Stanzione said that after years of cloud computing hype, artificial intelligence now demands traditional high performance computing architecture.

    Apr 23, 2024

  • Unlocking Targeted Cancer Care: Biomarkers as the Key to Personalized Treatments

    Bio-IT World | In modern medicine, biomarkers stand as pivotal indicators of biological processes or responses to therapeutic interventions, signaling a new era in clinical trial design and patient care. The driving idea behind the use of these tools is that by integrating the right biomarker information, scientists can properly select patients who are most likely to benefit from a particular therapy.

    Apr 19, 2024

  • New Products Win Praise at 2024 Bio-IT World Best of Show Awards

    Bio-IT World | Bio-IT World announced six Best of Show winners yesterday at the 2024 Bio-IT World Conference & Expo in Boston. Honored new products came from winning companies including Combinatics, Osprey, Maxis.IT, Nurocore, Velsera, and Xybion.

    Apr 16, 2024

  • Age of Opportunity: Artificial Intelligence and the Precision Medicine Future

    Bio-IT World | At the Precision Med TriConference 2024, Illumina Ventures partner Mara Aspinall sat with Eric Topol, endowed chair and executive VP and professor at Scripps Translational Science Institute, in a fireside chat to discuss precision medicine and artificial intelligence (AI). With three published books and more than 1,200 peer reviewed publications, Topol is one of the industry’s leading minds on digital medicine, and from his perspective, AI needs to be adapted sooner.

    Apr 16, 2024

  • Effects Of Genetic Mutations Become Knowable With ‘Super Minigene’ System

    Bio-IT World | Molecular biologists at Iowa State University report the potential for the effects of genetic mutations to be known using a “super minigene” system developed in the lab of Ravindra Singh, Ph.D., professor of biomedical sciences.

    Apr 11, 2024

  • Novel Predictive Model For Explaining How Anti-Fibrotic Drugs Work

    Bio-IT World | In drug discovery, the focus of machine learning and artificial intelligence tools has been on predicting outcomes without explanation or understanding of the biochemical pathways mediating those effects. But rigorous translation requires a solid science-based foundation to explain how a drug works, not just that it does.

    Apr 10, 2024

  • NVIDIA GTC Panel Explores the Role of Generative AI in Medicine

    Bio-IT World | During the NVIDIA GTC conference held at the San Jose Convention Center and online March 18-21, NVIDIA CEO Jensen Huang highlighted an array of advancements, including new foundation models coming to NVIDIA BioNeMo, a collaboration with Johnson & Johnson MedTech to expand AI’s role in surgical settings, and the launch of over two dozen generative AI microservices to advance areas like digital health, medical technology, and drug discovery.

    Apr 9, 2024

  • Bio-IT World Names 2024 Best of Show Finalists, People’s Choice Contenders

    Bio-IT World | Bio-IT World announced the 2024 Best of Show Finalists and People’s Choice Contenders today, highlighting 26 new products from 27 different companies that will be on display at the Bio-IT World Conference and Expo, April 15-17, in Boston. The Best of Show Awards will honor several new products live at the event during the Best of Show Awards Reception beginning at 5:15 on Tuesday, April 16.

    Apr 8, 2024

  • Enhancing CRISPR: Utilizing Single-Cell Multiomics for CRISPR-based Drug Product Analysis

    Bio-IT World | The pace at which CRISPR has transitioned from a research tool to a therapeutic modality is remarkable. Initially targeting genetic diseases, CRISPR holds tremendous promise across various indications, rapidly expanding into oncology and infectious diseases, indicating CRISPR's vast and continual evolution as a modality.

    Apr 5, 2024

  • RNA-Protein Complex Contributing To ‘Background Autoimmunity’ In Women

    Bio-IT World | The single biggest risk factor for autoimmune disease is being biologically a female and many explanations have been proposed as to why that is, among them sex hormones and the X chromosome with its large number of immune-related genes.

    Apr 3, 2024